- Home
- TYRA vs CBNK Comparison
TYRA vs CBNK Comparison
Compare TYRA & CBNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- CBNK
- Stock Information
- Founded
- TYRA 2018
- CBNK 1974
- Country
- TYRA United States
- CBNK United States
- Employees
- TYRA N/A
- CBNK N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- CBNK Major Banks
- Sector
- TYRA Health Care
- CBNK Finance
- Exchange
- TYRA Nasdaq
- CBNK Nasdaq
- Market Cap
- TYRA 667.3M
- CBNK 563.7M
- IPO Year
- TYRA 2021
- CBNK 2018
- Fundamental
- Price
- TYRA $12.11
- CBNK $33.11
- Analyst Decision
- TYRA Strong Buy
- CBNK Hold
- Analyst Count
- TYRA 8
- CBNK 1
- Target Price
- TYRA $31.00
- CBNK $35.00
- AVG Volume (30 Days)
- TYRA 243.4K
- CBNK 53.0K
- Earning Date
- TYRA 11-06-2025
- CBNK 10-27-2025
- Dividend Yield
- TYRA N/A
- CBNK 1.44%
- EPS Growth
- TYRA N/A
- CBNK 11.33
- EPS
- TYRA N/A
- CBNK 2.69
- Revenue
- TYRA N/A
- CBNK $205,155,000.00
- Revenue This Year
- TYRA N/A
- CBNK $47.22
- Revenue Next Year
- TYRA N/A
- CBNK $7.72
- P/E Ratio
- TYRA N/A
- CBNK $12.37
- Revenue Growth
- TYRA N/A
- CBNK 30.26
- 52 Week Low
- TYRA $6.42
- CBNK $24.10
- 52 Week High
- TYRA $29.60
- CBNK $36.40
- Technical
- Relative Strength Index (RSI)
- TYRA 54.50
- CBNK 45.37
- Support Level
- TYRA $11.70
- CBNK $33.50
- Resistance Level
- TYRA $12.91
- CBNK $35.00
- Average True Range (ATR)
- TYRA 0.67
- CBNK 0.74
- MACD
- TYRA -0.04
- CBNK -0.11
- Stochastic Oscillator
- TYRA 30.38
- CBNK 16.56
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.